Madden Securities’s Vertex Pharmaceuticals VRTX Stock Holding History

Madden Securities’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$26.1K	Buy	+50	New	+$25.6K	0.01%	229

Other funds holding VRTX

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $174B AUM 33.96% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $83.2B AUM 35.34% 1-Year Est. Return

AMF Tjänstepension Stockholm, Sweden $17.2B AUM 28.3% 1-Year Est. Return

Bank Julius Baer & Co Zurich, Switzerland $39.3B AUM 31.81% 1-Year Est. Return

ProShare Advisors Bethesda, Maryland $69.5B AUM 31.38% 1-Year Est. Return

Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $57B AUM 43.56% 1-Year Est. Return

Davenport & Co Richmond, Virginia $19.9B AUM 12.67% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $52.9B AUM 36.03% 1-Year Est. Return

Madden Securities's VRTX Position: Q3 2026 in Review

Madden Securities opened a new position in Vertex Pharmaceuticals (VRTX) in Q3 2026: 50 shares worth $26.1K. The stake represents 0.01% of the portfolio and ranks #229 among its holdings.

678 funds tracked by Wall St. Rank hold VRTX as of Q3 2026.

Madden Securities held 50 shares of Vertex Pharmaceuticals worth $26.1K as of Q3 2026.
Vertex Pharmaceuticals was a new Madden Securities position in Q3 2026.
Vertex Pharmaceuticals made up 0.01% of Madden Securities's portfolio in Q3 2026, its #229 holding.
678 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q3 2026.

Based on Madden Securities's 13F filing for Q3 2026, filed 27 Oct 2026.